Andrew Lobashevsky, MD, PhD
Professor of Medicine
Andrew Lobashevsky MD,PhD, D(ABHI)- Diplomat of American Board of Histocompatibility and Immunogenetics is Associate Professor and Histocompatibility Laboratory Director at Department of Medicine of Indiana University and Clarian Health Partners Inc. Dr. Andrew Lobashevsky joined the IU Department of Medicine in December 2004, as the Directory of the Immunology-Histocompatibility Laboratory. Previously, Dr. Lobashevsky was the Co-director of the HLA Laboratory at the University of Alabama at Birmingham Transplant Center, the third largest center in the country. Dr. Lobashevsky received his medical education and postgraduate training at the Department of Immunology and Microbiology of Sechenov’s Medical Academy, Moscow, Russia. He had his post-doctoral training in cellular and molecular immunology at the University of Tennessee at Memphis, and received transplant immunology/histocompatibility training at the University of Alabama at Birmingham. The laboratory headed by Dr. Lobashevsky is focused on providing service for the solid organ transplant programs as well as the bone marrow transplant activities of the Hematology/Oncology division at IU.
Riley Addition, Suite 0615 705 Riley Hospital Dr
Indianapolis, IN 46202-5128
Titles & Appointments
- Histocompatibility Laboratory Director at IUSM, Dept. of Medicine
- Transplant Immunology Laboratory Director at Methodist Hospital (Clarian Health partners Inc.)
In early 2005, the transplant program at IU initiated the use of desensitization protocols which include the use of intravenous immunoglobulin, both with and without plasmapheresis. Desensitization is widely used to decrease percent of reactive antibodies in solid organs transplant candidates. Various numbers of cycles of desensitization are required to decrease the level of donor specific antibodies. We hypothesized that there was a correlation between polymorphis of some cytokine genes and intensity of desensitization required to make the recipient/donor cross match compatible. The results of the study showed that analysis of polymorphism (SNP) of genes encoding IL-4R, IFNã and IL-12 enables to define thedesensitization strategy in transplant candidates more accurately regarding the number of plasmapheresis cycles and dose of intravenous immunoglobulin. Structural Basis of HLA Compatibility. I have been working on this project since 2004. Through factor analysis of the data, there was a significant contribution to understanding of the mechanism of humoral response to mismatched HLA in heart and kidney recipients. This project generated preliminary information about HLA epitope immunogenicity. My subsequent input in this project was related with submitting, analysis and discussion of the data generated on basis of antibody specificity/epitope/eplete analysis using highly sensitive LUMINEX solid phase method. This will have tremendous clinical impact on donor selection.
Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation.
Rapid and strong de novo donor-specific antibody development in a lung transplant recipient: Short communication/case report.
Prospective Monitoring of Donor-Specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.
The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates.
Impact of positive flow cytometry crossmatch on outcomes of intestinal/multivisceral transplantation: role anti-IL-2 receptor antibody.
Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
Identification of a novel HLA-DRB1 allele, DRB1*09:20, by sequence-based typing in an unrelated bone marrow donor.
Identification of a novel HLA-DQB1 allele, DQB1*05:19, in an African American family by sequence-based typing.
Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
Identification of a novel HLA-C allele, Cw*021602, by sequence-based typing in a family of German descent.
Identification of a novel HLA-A*680202 allele by sequence-based typing in an African American individual.
Identification of a novel HLA-DRB1 allele, DRB1*116502, by sequence-based typing in an African-American individual.
Desc: Structural analysis of histocompatibility antigens